Short Interest in Bionano Genomics, Inc. (NASDAQ:BNGO) Grows By 13.0%

Bionano Genomics, Inc. (NASDAQ:BNGO) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totalling 4,160,000 shares, an increase of 13.0% from the August 31st total of 3,680,000 shares. Currently, 6.1% of the company’s stock are sold short. Based on an average trading volume of 1,770,000 shares, the days-to-cover ratio is presently 2.4 days.

Analysts Set New Price Targets

BNGO has been the topic of several recent analyst reports. BTIG Research cut Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th. Scotiabank reiterated a “sector perform” rating and issued a $1.00 price target (down previously from $6.00) on shares of Bionano Genomics in a research note on Wednesday, August 28th.

Institutional Trading of Bionano Genomics

A number of institutional investors and hedge funds have recently made changes to their positions in BNGO. Virtu Financial LLC acquired a new stake in shares of Bionano Genomics during the 1st quarter worth approximately $36,000. Price T Rowe Associates Inc. MD raised its position in shares of Bionano Genomics by 123.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after purchasing an additional 38,900 shares during the period. Cantor Fitzgerald L. P. grew its holdings in Bionano Genomics by 22.2% in the 4th quarter. Cantor Fitzgerald L. P. now owns 55,000 shares of the company’s stock worth $104,000 after buying an additional 10,000 shares in the last quarter. Cetera Advisors LLC bought a new position in Bionano Genomics in the 1st quarter worth approximately $163,000. Finally, Quadrature Capital Ltd bought a new position in Bionano Genomics in the 4th quarter worth approximately $209,000. 11.35% of the stock is currently owned by institutional investors and hedge funds.

Bionano Genomics Stock Up 4.9 %

NASDAQ BNGO traded up $0.02 on Friday, hitting $0.46. 3,994,911 shares of the stock traded hands, compared to its average volume of 1,575,953. The stock has a 50-day moving average of $0.49 and a 200 day moving average of $0.75. Bionano Genomics has a twelve month low of $0.31 and a twelve month high of $3.08. The company has a market capitalization of $30.97 million, a P/E ratio of -0.08 and a beta of 2.31. The company has a current ratio of 1.63, a quick ratio of 1.11 and a debt-to-equity ratio of 0.04.

Bionano Genomics (NASDAQ:BNGO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter. Bionano Genomics had a negative net margin of 557.98% and a negative return on equity of 151.27%. The firm had revenue of $7.77 million for the quarter. As a group, analysts expect that Bionano Genomics will post -1.42 earnings per share for the current fiscal year.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.